173 related articles for article (PubMed ID: 18022011)
1. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
Rezvani K; Yong AS; Savani BN; Mielke S; Keyvanfar K; Gostick E; Price DA; Douek DC; Barrett AJ
Blood; 2007 Sep; 110(6):1924-32. PubMed ID: 17505014
[TBL] [Abstract][Full Text] [Related]
2. "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".
Cuvelier GDE; Li A; Drissler S; Kariminia A; Abdossamadi S; Rozmus J; Chanoine JP; Ng B; Mostafavi S; Brinkman RR; Schultz KR
Front Immunol; 2020; 11():571884. PubMed ID: 33193355
[TBL] [Abstract][Full Text] [Related]
3. [Pathogenesis and Therapeutic Prospects of Chronic Graft-Versus-Host Disease --Review].
Xu SH; Man Y; Zhao JL; Wang YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):647-652. PubMed ID: 38660881
[TBL] [Abstract][Full Text] [Related]
4. [Application and clinical significance of intercellular proximity labeling technique in chronic myelogenous leukemia].
Ai LL; Lai AL; Qin XH; Liu BC; Li J; Wang JX; Zhu P
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):543-549. PubMed ID: 37749032
[No Abstract] [Full Text] [Related]
5. Enrichment of effector memory T cells in the CD4 and CD8 T cell compartment during chronic graft versus host disease in children.
Parra-Ortega I; Nájera-Martínez N; Gaytán-Morales F; Castorena-Villa I; López-Martínez B; Ortiz-Navarrete V; Olvera-Gómez I
Transpl Immunol; 2023 Dec; 81():101951. PubMed ID: 37939887
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in chronic graft-versus-host disease.
Rozmus J; Schultz KR
Expert Rev Hematol; 2011 Jun; 4(3):329-42. PubMed ID: 21668397
[TBL] [Abstract][Full Text] [Related]
7. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.
Roberto A; Castagna L; Zanon V; Bramanti S; Crocchiolo R; McLaren JE; Gandolfi S; Tentorio P; Sarina B; Timofeeva I; Santoro A; Carlo-Stella C; Bruno B; Carniti C; Corradini P; Gostick E; Ladell K; Price DA; Roederer M; Mavilio D; Lugli E
Blood; 2015 Apr; 125(18):2855-64. PubMed ID: 25742699
[TBL] [Abstract][Full Text] [Related]
8. Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic stem cell tranplantation is predictive of subsequent relapse and survival.
Verma K; Croft W; Pearce H; Zuo J; Stephens C; Nunnick J; Kinsella FA; Malladi R; Moss P
Haematologica; 2023 Feb; 108(2):433-443. PubMed ID: 35924575
[TBL] [Abstract][Full Text] [Related]
9. Importance of TREC and KREC as molecular markers for immunological evaluation of down syndrome children.
Eissa E; Afifi HH; Abo-Shanab AM; Thomas MM; Taher MB; Kandil R; Kholoussi NM
Sci Rep; 2023 Sep; 13(1):15445. PubMed ID: 37723211
[TBL] [Abstract][Full Text] [Related]
10. Losing TREC with age.
Zhang SL; Bhandoola A
Immunity; 2012 Feb; 36(2):163-5. PubMed ID: 22365662
[TBL] [Abstract][Full Text] [Related]
11. T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.
Gaballa A; Sundin M; Stikvoort A; Abumaree M; Uzunel M; Sairafi D; Uhlin M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27727179
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.
Liu W; Ren HY; Dong YJ; Wang LH; Yin Y; Li Y; Qiu ZX; Cen XN; Shi YJ
Int J Hematol; 2012 Dec; 96(6):764-72. PubMed ID: 23179902
[TBL] [Abstract][Full Text] [Related]
13. Twisting immune responses for allogeneic stem cell therapy.
Li SC; Zhong JF
World J Stem Cells; 2009 Dec; 1(1):30-5. PubMed ID: 20975985
[TBL] [Abstract][Full Text] [Related]
14. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
15. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
18. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
